Bio Chemical Recurrence

//Bio Chemical Recurrence

18F-Fluciclovine PET/CT Superior to 11C-Choline PET/CT for the Detection of a Prostate Cancer Relapse

We have all been ever increasingly aware of the weakness of our scanning technologies when it comes to both diagnosing prostate cancer and its recurrence. Given that about 1/3 of all primary treatments for prostate cancer will fail and the cancer will return it is vital that we improve our ability to detect prostate cancer recurrences earlier. In recent years, there have been a few improved contrasts developed that have increased scanning sensitivity. Two competing contrasts are a new PET compound (anti-3-(18)F-FACBC or (18)F-fluciclovine) and (11)C-choline. Researchers set out to compare these two contrasts for their sensitivity to detect a [...]

Standardizing PSA Definition of Biochemical Recurrence after Radical Prostatectomy

There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to decide at what point additional treatment would most benefit a man with recurrent prostate cancer. To accomplish this goal researchers reviewed the long-term prostatectomy outcomes to assess the most appropriate prostate specific antigen cut point that predicts future disease progression. The study was large, including [...]

Comparing (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline PET/CT in Prostate Cancer Relapse

There has been a lot of hype and confusion about what is the best contrast for prostate cancer PET/CT scans. The two newest contrasts; (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline both have their supporters and their detractors. To try and evaluate the efficacy differences between these two contrasts in men who have suffered a bio-chemical recurrence after surgery researchers did a head to head evaluation of 100 consecutive men treated with surgery for prostate cancer and presenting with a rising PSA. All of the men had (11)C-choline and (18)F-FACBC PET/CTs performed within 1 week and were off hormonal therapy at the time [...]

Can Radiotherapy (Radiation) for the Primary Tumors Benefit Men With Prostate CancerWith Distant Metastasis at Initial Diagnosis?

The common belief is that if you are diagnosed with prostate cancer that has already developed metastases only a systemic treatment will provide a life extending benefit. In other cancers it has been shown that the treatment of the primary tumor improves survival (tumor debulking). To find out if, in fact radiotherapy treatment of the primary tumor in prostate cancer with distant metastasis would provide a similar positive benefit, researchers evaluated the efficacy and toxicity of radiotherapy of the primary tumor in prostate cancer in men with metastasis. The study included 140 men with metastatic prostate cancer at initial diagnosis. [...]